I used to subscribe to one of Dylan Jovine's newsletters. I would not recommend it. The typical monthly letter would be 8 pages about his latest stock pick, with about 7 of those pages charts, graphs, and tables about the stock he probably grabbed off a f[...]

Way back in the day in the early aughts I fell for "Dr" Lashmet's pitch for a company that he said had the cure for HIV and AIDS. Porter Stansberry used to tout "Dr" Lashmet as an expert on biotech. He failed to mention that "Dr" Lashmet received his phD i[...]

It is in fact Denali. Just got his email pitch. He put a picture of Denali CEO Ryan Watts in his email saying this man will cure Alzheimers. I did a Tineye image search and it was Ryan Watts.[...]

Yes Hive is good too for the reason you stated that it also mines ETH. All these Canadian miners will get a nice boost in their share price when they list for NASDAQ, which is anticipated sooner than later.[...]

I own many stocks in the cryptocurrency space. I do own Voyager. However, I think the best way to play this space is to own the most undervalued bitcoin miners. The major expense for miners is electricity, which is a fixed cost. However, the price of Bit[...]

This is old news and was dealt with in the early fall. The cleaning concern was encountered with Covid testing only. Abbott, Thermo Fisher and others all encountered the same issue with not having strong enough disinfectant (there is references for this) [...]

Lexagene is finally no longer just an R&D outfit, but an actual company with a real product. They announced this week the first sale of the MiQLab to a large multinational pharma company. The pharma will be using the MiQLab to test for contaminants in its[...]

Lou has a pretty good track record on his biotech stock picks. I used to subscribe to one of his paid letters, and get his free email updates now.Regarding 5G, I started tracking all these 5G stocks around the time we cracked the list of 5G stocks Geor[...]

I actually found a free site called aidedtrade (https://www.aidedtrade.io). Just click the "X" on the subscribe now popup that appears. 100% free and no registration or free trial nonsense.[...]

The yahoo finance message board for Cytodyn (CYDY), the company that owns leronlimab, is a good source of the latest info.[...]

There are screeners that you can pay a monthly fee and get this info. FlowAlgo (http://flowalgo.com) is an example of one. I would not pay any guru to feed me this info as he or she is probably front running the info.[...]

You might learn something about options, but you probably won't make money as is the case by following most of these gurus. Here is a review about his service: https://www.youtube.com/watch?v=a9HMwk8pnHc&t=650s[...]

Also wanted to say that I've been reading this site since it was founded and I'm a lifetime irregulars member. Travis you've saved me thousands by preventing me from subscribing to all these newsletters. So heartfelt thanks for all you do here.[...]

Not Gilder 5G stocks, but two that I like in this space are Atomera (ATOM) and Lumentum (LITE). Atomera is small cap while Lumentum isn't and had a nice run up last year.[...]

Unfortunately bought AKAO and learned my lesson. Never again will I buy a biotech company developing an antibiotic. There simply isn't enough profit potential even if the drug is approved.[...]

What I hate the most is these guys sell a "basic" newsletter (and you don't know its their basic version) and you get a pitch later on for the expensive newsletter where presumably the best investing ideas are located. You expect someone to give you their [...]

It's here: https://www.stockgumshoe.com/2020/04/microblog-george-gilders-dont-buy-5g-stocks-buy-15g-instead/[...]

Here are my guesses for far listed in the order in which he talks about them: 2. "Makes the sensors for self-driving cars" - Ambarella (AMBA) 3. "Merges AI and network security" - A10 Networks (ATEN) 6. "Safeguards the internet of things" - Allot (ALLT[...]

It's obvious that these days for the Motley Fool itself, selling newsletters is the #1 investment. Rather disappointing, because in the mid 90's when the Gardner brothers first wrote their book they seemed more interested in educating the public and financ[...]

MEI Pharma (MEIP). It was not hard for me to figure out with the clues he gave, most notably, MEI received FDA fast track approval in early April for its lymphoma drug and recently received a $100M investment from a foreign pharma.[...]